CJA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text (PDF)
Right arrow Submit a scholarly reply
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diemunsch, P.
Right arrow Articles by Hahne, W. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diemunsch, P.
Right arrow Articles by Hahne, W. F.

Canadian Journal of Anesthesia, Vol 44, 173-181, Copyright © 1997 by Canadian Anesthesiologists' Society

ARTICLES

Intravenous dolasetron mesilate ameliorates postoperative nausea and vomiting

P Diemunsch, J Leeser, P Feiss, A D'Hollander, BG Bradburn, D Paxton, J Whitmore, P Panouillot, S Nave, RA Brown and WF Hahne
Hopitaux Universitaires, Strasbourg, France.

PURPOSE: To compare the efficacy, safety, and tolerability of dolasetron mesilate with placebo for the treatment of postoperative nausea and vomiting (PONV). METHODS: In a randomized, multicentre, double-blind, placebo-controlled study 337 adult patients undergoing surgery with general anaesthesia received one of four single, doses of dolasetron mesilate iv (12.5, 25, 50, or 100 mg) or placebo. Study medication was administered postoperatively when the patient reported nausea lasting 10 min or when one emetic episode occurred within two hours of the patient's arrival in the recovery room. Efficacy was assessed by the investigators over the 24-hr study period by recording the number and timing of emetic episodes, the severity of nausea, the timing of administration of escape antiemetic medications, and patients' and investigators' satisfaction with antiemetic therapy. RESULTS: The study sample was predominately women, and the surgical procedures were primarily gynaecological. All dolasetron mesilate doses produced higher complete response rates than placebo (P < 0.05). Only approximately one-third of dolasetron patients required escape antiemetic medication compared with more than 50% of patients in the placebo group. Both patient and physician satisfaction with dolasetron treatment was high. The most common adverse event was mild or moderate headache for both placebo-treated patients and dolasetron-treated patients. Clinical laboratory results were unremarkable. CONCLUSION: Single doses of dolasetron mesilate iv, given after the first episode of PONV, were both effective and safe in this adult patient population.


This article has been cited by other articles:


Home page
 Anesth. Analg.Home page
X. Chen, J. Tang, P. F. White, R. H. Wender, R. Quon, A. Sloninsky, R. Naruse, R. Kariger, T. Webb, and E. Norel
The Effect of Timing of Dolasetron Administration on its Efficacy as a Prophylactic Antiemetic in the Ambulatory Setting
Anesth. Analg., October 1, 2001; 93(4): 906 - 911.
[Abstract] [Full Text] [PDF]

Home page
 Anesth. Analg.Home page
E. Zarate, M. F. Watcha, P. F. White, K. W. Klein, M. S. Rego, and D. G. Stewart
A Comparison of the Costs and Efficacy of Ondansetron Versus Dolasetron for Antiemetic Prophylaxis
Anesth. Analg., June 1, 2000; 90(6): 1352 - 1358.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the Canadian Anesthesiologists' Society.